Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Acromegaly 1

Interventions

fludarabine phosphate 2avelumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2Cyclophosphamide 2veliparib 1romidepsin 1pasireotide 1lutetium Lu 177 dotatate 1fludarabine 1entrectinib 1alectinib 1Temozolomide 1Specimen Handling 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Lutetium-177 1Lactones 1Interleukin-13 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Capecitabine 1Cabergoline 1Biopsy 1Biological Therapy 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Cabergoline × Dermatologic × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡